20 results about "Metabolic profile" patented technology

The invention discloses a rapid detection method for bloodstream infection pathogenic bacteria based on a rapid mass spectrometry technology, and belongs to the technical field of medical detection. Analyzing the metabolic gas of the blood flow infected pathogenic bacteria by using UVP-TOFMS to obtain a pathogenic bacteria metabolic profile spectrogram; preprocessing the obtained pathogenic bacterium metabolism profile spectrogram data; integrating the preprocessed pathogenic bacterium metabolism profile spectrogram data by using a stacking algorithm, and constructing a pathogenic bacterium identification model; evaluating the effectiveness of the pathogenic bacterium identification model on a training set and a test set through accuracy, precision, a confusion matrix and a subject operation curve; and comparing and screening characteristic metabolic markers of the pathogenic bacteria by combining the importance and significance of model characteristics, and indicating the types of the pathogenic bacteria. The method does not need sample pretreatment, is simple and convenient to operate, short in detection time (20 seconds per sample), high in accuracy and suitable for clinical popularization, and provides technical support for early diagnosis and treatment of bloodstream infection.

This invention discloses a pharmaceutical composition for treating asthenospermia by activating the Nrf2 / HO-1 / GPx4 pathway and its application. The pharmaceutical composition comprises taurine and geranium as active ingredients, wherein the mass ratio of taurine to geranium is 3-5:1. The pharmaceutical composition of this invention can synergistically activate the Nrf2 / HO-1 / GPx4 antioxidant signaling pathway, upregulate the expression of downstream antioxidant enzymes GPx4 and HO-1, inhibit lipid peroxidation, protect sperm mitochondrial function, and simultaneously improve the microenvironmental metabolic profile of the epididymis—the site of sperm maturation—thereby enhancing sperm motility. The pharmaceutical composition provided by this invention can be used to prepare a treatment for asthenospermia, particularly oxidative stress-induced asthenospermia.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and / or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and / or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

The invention discloses a group of diagnosis, typing and prognostic markers for children Langerhans cell histocytosis, and belongs to the technical field of disease diagnosis. In the invention, an overall metabolic profile of bone marrow aspirates (BMA) of 34 children LCH patients is analyzed, and the patients are divided into three subtypes: single system diseases (SS), multi-system diseases (MS-RO-) without dangerous organ tiredness and multi-system diseases (MS-RO +) with dangerous organ tiredness. The metabonomics characteristics of children diagnosed as LCH are described, the metabolic characteristics of a multi-system LCH (MS-RO +) group with dangerous organs being tired before and after treatment are comprehensively researched, and important metabolic markers for molecular diagnosis, subtype classification, treatment evaluation and prognosis are provided for children patients suffering from LCH, especially high-risk LCH.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

A pharmaceutical composition comprises a muscarinic agonist and a pharmacokinetic (PK) modifier that changes the metabolic profile the muscarinic agonist. The pharmaceutical composition may be used for the treatment of a neurological disorder or condition in a subject.

The invention relates to a neonatal genetic disease gene and metabolite combined screening method, system and equipment, and the method comprises the steps: carrying out the rapid detection of a plurality of metabolites on a neonatal biological sample, and obtaining metabolic spectrogram data; comparing the metabolic spectrogram data with a metabolic phenotype-genotype associated knowledge base, and automatically identifying an abnormal metabolic phenotype meeting a preset condition; in response to the identified abnormal metabolic phenotype, automatically triggering gene analysis of a specific gene corresponding to the target genetic disease in the same biological sample; based on the abnormal metabolic phenotype and the gene analysis result of the specific gene, a combined screening report is generated, so that accurate and efficient source tracing from a non-specific metabolic disorder index to a specific pathogenic gene source is achieved, and the purpose of providing an integrated screening and auxiliary diagnosis solution for neonatal genetic diseases is achieved.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's blood pressure. The platform implements a short-term prediction model to generate a daily prediction of the patient's blood pressure based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's blood pressure during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's diastolic and systolic blood pressure and updates a digital twin of the patient's metabolic profile.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of androstenediol, oxtenedioate, digydrouracil, heptanoylglutamine, pregnenetriol, sulfate, heptenoylglutamine, hexanoylglutamine, guanine, methylhexanoylglutamine, hexanoylglycine, hexenoylglycine, spermidine, diacetylspermine, acisoga and combinations thereof; and producing a metabolic profile for the metabolite.

The invention provides an application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product, and relates to the technical field of biomedicine, the technical key points are as follows: in the application, uremic pruritus micromolecular substances are found by using serum of a uremic patient to carry out a non-targeted metabonomics technology, and generally, the application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product has a good clinical application prospect. Metabolic profiles of serum from human subjects diagnosed with uremic pruritus, including pre-dialysis pruritus, post-dialysis transient remission, and non-remission of pre-dialysis pruritus, are determined. Metabolic profiles from the two groups of biological samples are compared, and differential molecules exist in the metabolic profiles from the two groups of patients suffering from uremic pruritus. According to the invention, through non-targeted metabonomics, a significantly different molecule catechin which the pruritus of a uremia patient is not relieved before and after dialysis and the pruritus is temporarily relieved after dialysis is screened out, the catechin is injected into the cheek part of a normal mouse, and the pruritus conditions of the two mouse models are detected through behavioristics. And the evidence of mouse pruritus caused by the catechin is provided through a verification test.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, alio-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The invention relates to a diagnostic index for hypertension grading and application thereof, and belongs to the technical field of biology. By screening catecholamine and hormone metabolic profiles in blood plasma of hypertensive patients and analyzing the relationship between different hypertension grading and cardiovascular adverse events and catecholamine and hormone levels, the corticotin level can be used as a diagnostic index of hypertension grading. The invention breaks through the traditional few index detection limitation, comprehensively detects a series of catecholamines and metabolites thereof, covers novel and less concerned methylation or oxidation modified derivatives and the like, deeply captures metabolic pathway changes, finds a new metabolic biomarker corticosin, fills up the blank of metabolite detection, and provides more molecular basis for accurate diagnosis; a more accurate and comprehensive diagnosis method is established, and excessive diagnosis of the secondary hypertension and missed diagnosis of the secondary hypertension are reduced, so that a patient can obtain targeted treatment.

The invention provides a plasma metabolism marker for kidney cancer diagnosis and application thereof, and belongs to the technical field of disease diagnosis. According to the invention, through comprehensive analysis and comparison of metabolic profiles of healthy people, kidney benign disease patients and kidney cancer patients, a group of metabolic marker combination with high specificity and significant difference is screened out, and the metabolic marker combination comprises 14 metabolic markers. As an end product of cell metabolic activity, the metabolic marker can more directly and sensitively reflect the abnormal metabolic state of tumor cells, so that early accurate recognition of kidney cancer and precancerous lesions is realized, the sensitivity of early diagnosis is remarkably improved, and the current clinical dilemma of'late stage once found 'is fundamentally reversed. The strategy is expected to greatly improve the survival rate and life quality of patients with kidney cancer, and a brand new path is provided for promoting precise medical treatment of kidney cancer.

This invention provides the application of metabolite biomarkers in the preparation of products for diagnosing hyperuricemia and a device for diagnosing hyperuricemia, belonging to the field of biomedical technology. This invention utilizes non-targeted metabolomics technology to systematically analyze the fecal metabolic profiles of a population cohort, and comprehensively employs differential analysis, partial least squares discriminant analysis (PLS-DA), and machine learning algorithms to screen and identify core fecal metabolic biomarkers (caustic acid, cowagarcinone E, and tuliposide B) from a massive amount of metabolites that can reliably predict the tendency to develop hyperuricemia. Finally, a predictive device based on this biomarker combination was established. This device has high predictive accuracy and provides a novel, non-invasive tool with high clinical translational potential for early screening and risk stratification of hyperuricemia.